Nuzenio

Nmpa Accepts New

Nmpa Accepts New news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 5 latest news signals 5 publisher sources 100/100 entity strength

Latest news

China accepts NDA for Alebund's phosphate binder AP301 after Phase III success - AllSciAllSci · Fri, 07 Aug 2026 16:31:47 GMTChina-ready by design: Leveraging NMPA’s new 30‑working day IND pathway - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 07:23:11 GMTNMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC - Macau BusinessMacau Business · Fri, 31 Jul 2026 09:10:29 GMTKelun-Biotech's Sac-TMT Gains NMPA Review for First-Line Advanced TNBC Indication - BioPharm InternationalBioPharm International · Thu, 30 Jul 2026 17:19:38 GMTCspc Pharmaceutical Says Nmpa Accepts New Drug Application For Sirolimus For Injection (Albumin-Bound) - TradingViewTradingView · Mon, 27 Jul 2026 15:17:27 GMT

Timeline

Fri, 07 Aug 2026 16:31:47 GMTChina accepts NDA for Alebund's phosphate binder AP301 after Phase III success - AllSci
Fri, 07 Aug 2026 07:23:11 GMTChina-ready by design: Leveraging NMPA’s new 30‑working day IND pathway - Pharmaceutical Technology
Fri, 31 Jul 2026 09:10:29 GMTNMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC - Macau Business
Thu, 30 Jul 2026 17:19:38 GMTKelun-Biotech's Sac-TMT Gains NMPA Review for First-Line Advanced TNBC Indication - BioPharm International
Mon, 27 Jul 2026 15:17:27 GMTCspc Pharmaceutical Says Nmpa Accepts New Drug Application For Sirolimus For Injection (Albumin-Bound) - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Nmpa Accepts New.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.